Research ExplorerPublicationsRegional differences in clear cell metastatic renal cell car...

Regional differences in clear cell metastatic renal cell carcinoma patients across the USA

Standard

Regional differences in clear cell metastatic renal cell carcinoma patients across the USA. / Scheipner, Lukas; Tappero, Stefano; Piccinelli, Mattia Luca; Barletta, Francesco; Garcia, Cristina Cano; Incesu, Reha-Baris; Morra, Simone; Baudo, Andrea; Tian, Zhe; Saad, Fred; Shariat, Shahrokh F; Terrone, Carlo; De Cobelli, Ottavio; Briganti, Alberto; Chun, Felix K H; Tilki, Derya; Longo, Nicola; Carmignani, Luca; Pichler, Martin; Hutterer, Georg; Ahyai, Sascha; Karakiewicz, Pierre I.

In: WORLD J UROL, Vol. 41, No. 11, 11.2023, p. 2991-3000.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Scheipner, L, Tappero, S, Piccinelli, ML, Barletta, F, Garcia, CC, Incesu, R-B, Morra, S, Baudo, A, Tian, Z, Saad, F, Shariat, SF, Terrone, C, De Cobelli, O, Briganti, A, Chun, FKH, Tilki, D, Longo, N, Carmignani, L, Pichler, M, Hutterer, G, Ahyai, S & Karakiewicz, PI 2023, 'Regional differences in clear cell metastatic renal cell carcinoma patients across the USA', WORLD J UROL, vol. 41, no. 11, pp. 2991-3000. https://doi.org/10.1007/s00345-023-04589-4

APA

Scheipner, L., Tappero, S., Piccinelli, M. L., Barletta, F., Garcia, C. C., Incesu, R-B., Morra, S., Baudo, A., Tian, Z., Saad, F., Shariat, S. F., Terrone, C., De Cobelli, O., Briganti, A., Chun, F. K. H., Tilki, D., Longo, N., Carmignani, L., Pichler, M., ... Karakiewicz, P. I. (2023). Regional differences in clear cell metastatic renal cell carcinoma patients across the USA. WORLD J UROL, 41(11), 2991-3000. https://doi.org/10.1007/s00345-023-04589-4

Vancouver

Scheipner L, Tappero S, Piccinelli ML, Barletta F, Garcia CC, Incesu R-B et al. Regional differences in clear cell metastatic renal cell carcinoma patients across the USA. WORLD J UROL. 2023 Nov;41(11):2991-3000. https://doi.org/10.1007/s00345-023-04589-4

Bibtex

@article{006dbb2213ea49d89a94000fa63c3ef1,
title = "Regional differences in clear cell metastatic renal cell carcinoma patients across the USA",
abstract = "PURPOSE: To test for regional differences in clear cell metastatic renal cell carcinoma (ccmRCC) patients across the USA.METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (2000-2018) was used to tabulate patient (age at diagnosis, sex, race/ethnicity), tumor (N stage, sites of metastasis) and treatment characteristics (proportions of nephrectomy and systemic therapy), according to 12 SEER registries. Multinomial regression models, as well as multivariable Cox regression models, tested the overall mortality (OM) adjusting for those patient, tumor and treatment characteristics.RESULTS: In 9882 ccmRCC patients, registry-specific patient counts ranged from 4025 (41%) to 189 (2%). Differences across registries existed for sex (24-36% female), race/ethnicity (1-75% non-Caucasian), N stage (N1 25-35%, NX 3-13%), proportions of nephrectomy (44-63%) and systemic therapy (41-56%). Significant inter-registry differences remained after adjustment for proportions of nephrectomy (46-63%) and systemic therapy (35-56%). Unadjusted 5-year OM ranged from 73 to 85%. In multivariable analyses, three registries exhibited significantly higher OM (SEER registry 5: hazard ratio (HR) 1.20, p = 0.0001; SEER registry 7:HR 1.15, p = 0.008M SEER registry 10: HR 1.15, p = 0.04), relative to the largest reference registry (n = 4025).CONCLUSION: Important regional differences including patient, tumor and treatment characteristics exist, when ccmRCC patients included in the SEER database are studied. Even after adjustment for these characteristics, important OM differences persisted, which may require more detailed analyses to further investigate these unexpected differences.",
keywords = "Humans, Female, Male, Carcinoma, Renal Cell/epidemiology, Kidney Neoplasms/pathology, SEER Program, Proportional Hazards Models, Nephrectomy/methods",
author = "Lukas Scheipner and Stefano Tappero and Piccinelli, {Mattia Luca} and Francesco Barletta and Garcia, {Cristina Cano} and Reha-Baris Incesu and Simone Morra and Andrea Baudo and Zhe Tian and Fred Saad and Shariat, {Shahrokh F} and Carlo Terrone and {De Cobelli}, Ottavio and Alberto Briganti and Chun, {Felix K H} and Derya Tilki and Nicola Longo and Luca Carmignani and Martin Pichler and Georg Hutterer and Sascha Ahyai and Karakiewicz, {Pierre I}",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = nov,
doi = "10.1007/s00345-023-04589-4",
language = "English",
volume = "41",
pages = "2991--3000",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "11",

}

RIS

TY - JOUR

T1 - Regional differences in clear cell metastatic renal cell carcinoma patients across the USA

AU - Scheipner, Lukas

AU - Tappero, Stefano

AU - Piccinelli, Mattia Luca

AU - Barletta, Francesco

AU - Garcia, Cristina Cano

AU - Incesu, Reha-Baris

AU - Morra, Simone

AU - Baudo, Andrea

AU - Tian, Zhe

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Terrone, Carlo

AU - De Cobelli, Ottavio

AU - Briganti, Alberto

AU - Chun, Felix K H

AU - Tilki, Derya

AU - Longo, Nicola

AU - Carmignani, Luca

AU - Pichler, Martin

AU - Hutterer, Georg

AU - Ahyai, Sascha

AU - Karakiewicz, Pierre I

N1 - © 2023. The Author(s).

PY - 2023/11

Y1 - 2023/11

N2 - PURPOSE: To test for regional differences in clear cell metastatic renal cell carcinoma (ccmRCC) patients across the USA.METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (2000-2018) was used to tabulate patient (age at diagnosis, sex, race/ethnicity), tumor (N stage, sites of metastasis) and treatment characteristics (proportions of nephrectomy and systemic therapy), according to 12 SEER registries. Multinomial regression models, as well as multivariable Cox regression models, tested the overall mortality (OM) adjusting for those patient, tumor and treatment characteristics.RESULTS: In 9882 ccmRCC patients, registry-specific patient counts ranged from 4025 (41%) to 189 (2%). Differences across registries existed for sex (24-36% female), race/ethnicity (1-75% non-Caucasian), N stage (N1 25-35%, NX 3-13%), proportions of nephrectomy (44-63%) and systemic therapy (41-56%). Significant inter-registry differences remained after adjustment for proportions of nephrectomy (46-63%) and systemic therapy (35-56%). Unadjusted 5-year OM ranged from 73 to 85%. In multivariable analyses, three registries exhibited significantly higher OM (SEER registry 5: hazard ratio (HR) 1.20, p = 0.0001; SEER registry 7:HR 1.15, p = 0.008M SEER registry 10: HR 1.15, p = 0.04), relative to the largest reference registry (n = 4025).CONCLUSION: Important regional differences including patient, tumor and treatment characteristics exist, when ccmRCC patients included in the SEER database are studied. Even after adjustment for these characteristics, important OM differences persisted, which may require more detailed analyses to further investigate these unexpected differences.

AB - PURPOSE: To test for regional differences in clear cell metastatic renal cell carcinoma (ccmRCC) patients across the USA.METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (2000-2018) was used to tabulate patient (age at diagnosis, sex, race/ethnicity), tumor (N stage, sites of metastasis) and treatment characteristics (proportions of nephrectomy and systemic therapy), according to 12 SEER registries. Multinomial regression models, as well as multivariable Cox regression models, tested the overall mortality (OM) adjusting for those patient, tumor and treatment characteristics.RESULTS: In 9882 ccmRCC patients, registry-specific patient counts ranged from 4025 (41%) to 189 (2%). Differences across registries existed for sex (24-36% female), race/ethnicity (1-75% non-Caucasian), N stage (N1 25-35%, NX 3-13%), proportions of nephrectomy (44-63%) and systemic therapy (41-56%). Significant inter-registry differences remained after adjustment for proportions of nephrectomy (46-63%) and systemic therapy (35-56%). Unadjusted 5-year OM ranged from 73 to 85%. In multivariable analyses, three registries exhibited significantly higher OM (SEER registry 5: hazard ratio (HR) 1.20, p = 0.0001; SEER registry 7:HR 1.15, p = 0.008M SEER registry 10: HR 1.15, p = 0.04), relative to the largest reference registry (n = 4025).CONCLUSION: Important regional differences including patient, tumor and treatment characteristics exist, when ccmRCC patients included in the SEER database are studied. Even after adjustment for these characteristics, important OM differences persisted, which may require more detailed analyses to further investigate these unexpected differences.

KW - Humans

KW - Female

KW - Male

KW - Carcinoma, Renal Cell/epidemiology

KW - Kidney Neoplasms/pathology

KW - SEER Program

KW - Proportional Hazards Models

KW - Nephrectomy/methods

U2 - 10.1007/s00345-023-04589-4

DO - 10.1007/s00345-023-04589-4

M3 - SCORING: Journal article

C2 - 37755519

VL - 41

SP - 2991

EP - 3000

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 11

ER -